Clal Insurance Enterprises Holdings Ltd Sells 4,000 Shares of Sanofi (NASDAQ:SNY)

Clal Insurance Enterprises Holdings Ltd decreased its holdings in Sanofi (NASDAQ:SNY) by 16.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,000 shares of the company’s stock after selling 4,000 shares during the quarter. Clal Insurance Enterprises Holdings Ltd’s holdings in Sanofi were worth $1,153,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Manning & Napier Advisors LLC bought a new position in Sanofi during the second quarter worth about $13,725,000. Mount Yale Investment Advisors LLC lifted its position in shares of Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after buying an additional 12,806 shares during the period. GFS Advisors LLC lifted its position in shares of Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after buying an additional 11,655 shares during the period. Atria Investments Inc boosted its stake in Sanofi by 31.1% in the 1st quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock valued at $4,805,000 after buying an additional 23,463 shares in the last quarter. Finally, Legacy Capital Wealth Partners LLC grew its position in Sanofi by 114.2% in the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock valued at $1,399,000 after acquiring an additional 12,942 shares during the period. 10.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Shares of SNY stock opened at $48.28 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a market capitalization of $122.53 billion, a PE ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock’s fifty day moving average is $53.70 and its 200-day moving average is $52.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. The company’s revenue was up 12.3% on a year-over-year basis. Equities research analysts expect that Sanofi will post 4.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.